Drugs / OMIPALISIB
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01725139 | Mar 2013 → Jul 2016 | idiopathic pulmonary fibrosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01248858 | Dec 2010 → Jan 2014 | cancer | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00972686 | Aug 2009 → Dec 2012 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMIPALISIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1236962 ↗ |
| Known as | GSK2126458 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01725139 ↗ |
| Action | Inhibit | “Phosphoinositide 3-Kinase Inhibitor GSK2126458” NCT00972686 ↗ |
| Modality | Small molecule | — CHEMBL1236962 ↗ |
| Route | Oral | “Subjects with solid tumors or lymphoma will initially receive oral GSK2126458 daily for 28 consecutive days in each 28 day cycle” NCT00972686 ↗ |
| Target | MTOR | “GSK2126458 is a novel, potent, PI3K/mammalian target of rapamycin (mTOR) inhibitor” PMID 27103349 ↗ Apr 2016 |